#United States #California #Class Action #Pomerantz LLP #Atara Biotherapeutics

Pomerantz Law Firm Initiates Class Action Lawsuit Against Atara Biotherapeutics

On April 9, 2026, Pomerantz LLP released information highlighting the initiation of a class action lawsuit targeting Atara Biotherapeutics, Inc. and certain of its top officials. This legal action arises out of allegations related to potentially misleading statements regarding the company’s financial and operational status during a specified period.

Background of the Lawsuit

The class action lawsuit has been filed in the United States District Court for the Central District of California, and is documented under docket number 26-cv-03083. The plaintiffs represent all individuals and entities that acquired Atara securities from May 20, 2024, to January 9, 2026. The suit aims to recover damages stemming from violations of federal securities laws, specifically under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5.

Call for Lead Plaintiff

Investors who engaged in the purchase or acquisition of Atara securities during the specified Class Period have until May 22, 2026, to step forward and request to be appointed as Lead Plaintiff in this class action. Interested parties can obtain a copy of the complaint on the Pomerantz website or reach out to representative Danielle Peyton through email or by phone. It is recommended that inquiries include relevant personal information.

Overview of Atara Biotherapeutics

Atara Biotherapeutics is known for developing innovative treatments targeting various health conditions, including solid tumors and autoimmune diseases, with a focus on therapies like tabelecleucel, which is designed for patients suffering from Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

The company works in partnership with Pierre Fabre Médicament for the commercialization of tabelecleucel. Atara's operational funding relies heavily on milestone payments from this partnership, contingent upon the achievement of specific developmental milestones related to tabelecleucel.

Regulatory Challenges

In May 2024, Atara announced its submission of a Biologics License Application (BLA) to the FDA for tabelecleucel as a standalone treatment for EBV+ PTLD in both adults and children older than two years who have previously undergone therapy. This application was allegedly bolstered by results from the company’s Phase 3 ALLELE study.

However, the lawsuit alleges that throughout the Class Period, the defendants made materially false statements and failed to disclose significant issues related to the manufacturing process and deficiencies within the ALLELE study. These undisclosed concerns allegedly revealed a low likelihood of FDA approval for tabelecleucel, contradicting the optimistic claims made by the company.

Stock Price Reactions

The implications of these legal challenges became evident when Atara faced regulatory setbacks in early 2025. On January 16, 2025, the company disclosed receipt of a Complete Response Letter from the FDA, indicating that the regulatory body would not approve the BLA in its current format due to issues uncovered during a pre-license inspection. Following this revelation, Atara's stock price took a drastic downturn, plummeting by 40.5% in one day.

Subsequently, the company encountered further regulatory difficulties, including a clinical hold on its Investigational New Drug applications. These setbacks led to additional significant declines in stock value, underscoring the market's reaction to the deteriorating prospects for tabelecleucel.

Continued Transparency Issues

In early 2026, Atara announced another setback with the FDA when it issued an additional CRL upon resubmission of the BLA, reinforcing the notion that the clinical trial design and outcomes were insufficient for demonstrating effectiveness. This further drove the stock price down, demonstrating the market's critical response to the company's failure to deliver on its promises.

Conclusion and Next Steps

Pomerantz LLP, recognized for its expertise in corporate and securities class litigation, continues to champion the rights of investors. The firm has a lengthy history of advocating for victims of fraud, with billions recovered on behalf of affected parties over its illustrious history. Investors and stakeholders following the developments surrounding Atara Biotherapeutics should remain informed about the proceedings and the potential ramifications on the company's future.

To learn more about the class action lawsuit, potential participation, or the allegations against Atara, stakeholders are encouraged to reach out to Pomerantz LLP or visit their website for additional details.